Search form
Search
Login
Subscribe
Home
Country Intelligence
Industry Directory
Offsets / IC
Tenders
India
(12/week)
Australia
(12/week)
Philippines
(1/week)
Haiti
(0/week)
Jamaica
(0/week)
View all
(25/week)
News
United States
(1029/week)
Manufacturing
(493/week)
Technology
(1033/week)
Energy
(378/week)
Other Manufacturing
(323/week)
Events
About us
Who we are
Our People
Partners
Contact us
LinkedIn
Login
Twitter
Register
Home
News
Bendamustine
Jul 12, 2019
Global Treanda (bendamustine; Teva/Mundipharma/Eisai Drug Overview & Product Profiles 2017-2026
Dec 01, 2018
AbbVie Presents New Data from Phase 3 MURANO Trial of VENCLEXTA®/VENCLYXTO® (venetoclax) in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Who Completed the Fixed Treatment Course
Dec 01, 2018
Major Trials Show Benefits of New Therapy Regimens for Cancer and Blood Disorders
Nov 01, 2018
AbbVie Receives European Commission Approval of VENCLYXTO® (venetoclax) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy
Sep 11, 2018
Minimal Residual Disease Negativity Data, a Measure of Undetectable Disease, Added to VENCLEXTA® (venetoclax tablets) Label
Jun 16, 2018
European Hematology Association: Answering the Unmet Need in One of the Most Common Types of Lymphoma: It's as Simple as A-D-C
Jun 15, 2018
AbbVie Announces New Undetectable Minimal Residual Disease Data from Phase 3 Relapsed/Refractory Chronic Lymphocytic Leukemia MURANO Trial of Venetoclax in Combination with Rituximab at 23rd European Hematology Association Annual Congress
Jun 08, 2018
AbbVie Announces U.S. FDA Approval of VENCLEXTA® (venetoclax tablets) in Combination with Rituximab as a Fixed Duration Treatment for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Patients Who Have Received One Prior Therapy
Dec 12, 2017
Late-Breaking Clinical Trials Signal New Therapeutic Options for Many Patients in the Near Term
Dec 12, 2017
AbbVie Announces Phase 3 Study of VENCLEXTA(TM)/ VENCLYXTO(TM) (venetoclax) in Combination with Rituxan® (rituximab) Meets its Primary Endpoint
Latest News
May 30, 2024
Interface Releases 2024 Design Trend Index
May 30, 2024
Cirium’s Emerald Sky Set to Transform Aircraft Emissions and Fuel Burn Data Accuracy
May 29, 2024
Japanese Construction Equipment Market to Reach 156,791 Units by 2029 with Infrastructure Investment Surge -...
May 29, 2024
VicOne Partners with 42Crunch to Deliver Uniquely Comprehensive Security Across SDV and Connected-Vehicle...
May 29, 2024
Global Advanced Aerospace Materials Market Forecast Report to 2028 - ResearchAndMarkets.com
May 29, 2024
OQ Chemicals Lifts Force Majeure for German Sites
May 29, 2024
Onera Presents New Clinical Data featuring the Innovative Onera STS at SLEEP 2024
May 29, 2024
Tricentis Appoints Former SAP Global Chief Architect as Field Chief Technology Officer, Americas
View all News
Agenda
29
October
United Kingdom
Copthorne Tara Hotel, London, UK
International Dismounted Soldier, 29-30 October 2024, Copthorne Tara Hotel, London, UK
Navigating the Evolving Battlespace: Enhancing the Capabilities of the Dismounted Soldier The modern battlefield...
24
September
United Kingdom
Hilton London Syon Park, London, UK
Defence Transformation Conference, 24-26 September 2024, Hilton London Syon Park, London, UK
Returning for its 8th year, Defence Transformation 2024 will feature an updated format that will address all aspects of...
17
June
France
Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024, 17 - 21 June 2024, Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024 There can be no sustainable world without peace and security. Founded in 1967, the exhibition...
View All Events